Paper
0
Valganciclovir for Symptomatic Congenital Cytomegalovirus Disease
Authors
David Kimberlin,Penelope Jester
Pablo Sánchez,Amina Ahmed,Ravit Arav‐Boger,Marian Michaels,Negar Ashouri,Janet Englund,Benjamin Estrada,Richard Jacobs,José Romero,Sunil Sood,M. Whitworth,Mark Abzug,Mary Caserta,Sandra Fowler,Jorge Luján‐Zilbermann,Gregory Storch,Roberta DeBiasi,Jin-Young Han,A. Palmer,Leonard Weiner,Joseph Bocchini,Penelope Dennehy,Adam Finn,Paul Griffiths,Suzanne Luck,Kathleen Gutierrez,Natasha Halasa,James Homans,Andi Shane,Mike Sharland,Kari Simonsen,John Vanchiere,Charles Woods,Diane Sabo,Inmaculada Aban,Hui‐Chien Kuo,Scott James,Mark Prichard,J Griffin,Dusty Giles,Edward Acosta,Richard Whitley
+42 authors
,Jin HanPublished
Mar 4, 2015
Show more
Save
Tip0
TipSave
Abstract
The treatment of symptomatic congenital cytomegalovirus (CMV) disease with intravenous ganciclovir for 6 weeks has been shown to improve audiologic outcomes at 6 months, but the benefits wane over time.
Paper PDF
This paper's license is marked as closed access or non-commercial and cannot be viewed on ResearchHub. Visit the paper's external site.